Lexicon Pharmaceuticals, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014; balance-sheet comparisons are with December 31, 2013. Lexicon is a clinical-stage biopharmaceutical company focused primarily on LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome. Revenue has principally come from collaborations and licenses, not product sales.
Financial performance and position
- Revenue: $0.277 million, down 23% from $0.360 million a year earlier. Collaborative research revenue fell to $0.172 million from $0.284 million, primarily due to lower Taconic Farms alliance revenue; subscription and license fees were $0.105 million versus $0.076 million.
- Expenses and loss: Research and development expense was $23.953 million, up 18%; general and administrative expense was $5.654 million, up 31%. Operating loss was $30.472 million versus $25.555 million; net loss was $30.835 million versus $25.974 million. Basic and diluted loss per share was $0.06 versus $0.05.
- Margins: The filing does not present a meaningful gross margin; the company reported minimal collaboration and license revenue against substantial operating expenses.
- Cash flow: Operating cash use was $30.319 million versus $24.271 million. Investing activities provided $40.568 million, mainly from net investment maturities; financing activities used $1.231 million, including $0.887 million of share repurchases and $0.420 million of debt repayments. Cash and cash equivalents increased by $9.018 million to $46.517 million.
- Liquidity: Cash, cash equivalents and short-term investments totaled $98.367 million at quarter-end, down from $129.128 million at year-end. Management said available resources and expected receipts should fund operations for at least 12 months; further financing may be required thereafter if operating cash generation is insufficient.
- Debt and liabilities: Mortgage principal was $21.5 million, at a fixed 8.23% rate, with maturity extended to April 2017. Balance-sheet current and long-term debt totaled approximately $21.5 million. Total liabilities were $102.825 million; accumulated deficit was $1.035 billion.
Material changes and unusual items
- In January, the board decided to narrow strategic initiatives and focus resources on late-stage programs, principally LX4211 and telotristat etiprate. The plan calls for reducing the workforce by approximately 125 employees, or about 50%, with most reductions expected by the end of Q2 2014.
- Restructuring cash charges are estimated at $5.8–$6.3 million, including about $5.3 million in severance. $4.0 million had been incurred through March 31, including $3.6 million in R&D and $0.4 million in G&A; $1.1 million of future restructuring payments was accrued at quarter-end. The filing also reports $0.1 million of stock-based compensation from accelerated vesting.
- R&D cost increases reflected higher personnel costs, including severance, and greater external clinical-development spending. G&A increases included severance and consulting costs related to commercialization preparation.
- The fair value of the Symphony Icon purchase consideration liability rose by $1.142 million in Q1, recorded as expense; its Level 3 balance was $28.852 million at quarter-end. The arrangement also provides for up to $45 million of contingent payments tied to specified licensing proceeds or other stated conditions.
- The company disclosed potential Texas Enterprise Fund repayment exposure of up to approximately $14.2 million if specified job-creation obligations are not met, before applicable credits. It also guarantees a subsidiary’s lease, with maximum potential future payments of $4.1 million.
Outlook, commentary and risks
Management provided no specific quarterly or full-year revenue or earnings guidance. It expects continued significant R&D spending and losses, and notes that future revenue depends on collaborations, milestones, royalties and successful development. Management said current unrestricted cash and investments, together with expected collaboration and licensing receipts, should cover at least the next 12 months. The filing cautions that additional capital may be needed and may not be available on acceptable terms.
Key risks include clinical-trial failure or delay, regulatory uncertainty, inability to commercialize or secure reimbursement, dependence on collaborators and third-party manufacturers, intellectual-property disputes, financing needs, and volatility in operating results. Lexicon reported no legal proceedings it believed would have a material adverse effect. Management concluded disclosure controls were effective and reported no significant changes in internal control during the quarter.
Most important facts for investors to verify
- Whether the workforce reduction and $5.8–$6.3 million restructuring estimate were completed as expected, and the resulting savings and cash costs.
- Clinical and regulatory progress for LX4211 and telotristat etiprate, and whether either program generates licensing, milestone or other revenue.
- Cash burn against the stated minimum 12-month liquidity outlook, including the timing and availability of collaboration receipts or new financing.
- Potential Symphony Icon contingent payments and the valuation assumptions behind its Level 3 liability.
- Progress toward Texas job-creation obligations and any resulting repayment exposure.